Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.

被引：1
|
作者：
Sartor, A. O.
Oudard, S.
Ozguroglu, M.
Hansen, S.
Machiels, J. H.
Shen, L.
De Bono, J. S.
机构：
[1] Tulane Sch Med, New Orleans, LA USA
[2] George Pompidou European Hosp, Paris, France
[3] Istanbul Univ, Cerrahpasa Med Fac, Dept Med Oncol, Istanbul, Turkey
[4] Odense Univ Hosp, DK-5000 Odense, Denmark
[5] Catholic Univ Louvain, Ctr Canc, Clin Univ St Luc, B-1200 Brussels, Belgium
[6] Sanofi Aventis, Malvern, PA USA
[7] Inst Canc Res, Sutton, Surrey, England
[8] Royal Marsden Hosp, Sutton, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4525
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4525
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Double-blind randomized trial of aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC)
    Tannock, Ian
    Fizazi, Karim
    Ivanov, Sergey
    Thellenberg-Karlsson, Camilla
    Flechon, Aude
    Skoneczna, Iwona Anna
    Orlandi, Francisco Jorquera
    Gravis, Gwenaelle
    Matveev, Vsevolod
    Bavbek, Sevil E.
    Gil, Thierry
    Viana, Luciano S.
    Aren, Osvaldo
    Karyakin, Oleg
    Elliott, Tony
    Birtle, Alison J.
    Magherini, Emmanuelle
    Petrylak, Daniel Peter
    Tombal, Bertrand
    Rosenthal, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Cohort compassionate-use program and early access program with cabazitaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: analysis by age group
    Malik, Z.
    Di Lorenzo, G.
    Bracarda, S.
    Ardavanis, A.
    Basaran, M.
    Parente, P.
    De Schultz, W.
    Saad, F.
    Van Oort, I.
    Gerritsen, W. R.
    Anton Aparicio, L. M.
    Matus, G.
    Hitier, S.
    Heidenreich, A.
    Bahl, A.
    BJU INTERNATIONAL, 2015, 115 : 61 - 62
  • [43] TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer
    Oudard, Stephane
    FUTURE ONCOLOGY, 2011, 7 (04) : 497 - 506
  • [44] Response to cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) poorly responding to docetaxel
    Angelergues, A.
    Bellmunt, J.
    Efstathiou, E.
    Gonzalez, I.
    Gyftaki, R.
    Delanoy, N.
    Ozguroglu, M.
    Flechon, A.
    Guillot, A.
    Le Moulec, S.
    Castellano, D.
    Esteban, E.
    Munarriz, J.
    Campos Balea, B.
    Ardavanis, A.
    Stefanou, D.
    Oudard, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S488 - S488
  • [45] Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
    Ning, Yang-Min
    Gulley, James L.
    Arlen, Philip M.
    Woo, Sukyung
    Steinberg, Seth M.
    Wright, John J.
    Parnes, Howard L.
    Trepel, Jane B.
    Lee, Min-Jung
    Kim, Yeong Sang
    Sun, Haihao
    Madan, Ravi A.
    Latham, Lea
    Jones, Elizabeth
    Chen, Clara C.
    Figg, William D.
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) : 2070 - 2076
  • [46] Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC).
    George, Daniel J.
    Halabi, Susan
    Healy, Patrick
    Gemberling, Sarah
    Winters, Carolyn
    Mundy, Kelly
    Harrison, Michael Roger
    Szmulewitz, Russell Zelig
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [47] Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer
    Madan, Ravi A.
    Karzai, Fatima H.
    Ning, Yang-Min
    Adesunloye, Bamidele A.
    Huang, Xuan
    Harold, Nancy
    Couvillon, Anna
    Chun, Guinevere
    Cordes, Lisa
    Sissung, Tristan
    Beedie, Shaunna L.
    Dawson, Nancy A.
    Theoret, Marc R.
    McLeod, David G.
    Rosner, Inger
    Trepel, Jane B.
    Lee, Min-Jung
    Tomita, Yusuke
    Lee, Sunmin
    Chen, Clara
    Steinberg, Seth M.
    Arlen, Philip M.
    Gulley, James L.
    Figg, William D.
    Dahut, William L.
    BJU INTERNATIONAL, 2016, 118 (04) : 590 - 597
  • [48] CABAZITAXEL PLUS PREDNISONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: AUSTRALIAN EARLY ACCESS PROGRAM SAFETY AND QUALITY OF LIFE ANALYSES
    Ng, S.
    Parnis, F.
    Guminski, A.
    Gurney, H.
    Parente, P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 60 - 61
  • [49] A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.
    Bavbek, Sevil E.
    Malik, Zafar I.
    Di Lorenzo, Giuseppe
    Scholz, Hans-Jorg
    van Oort, Inge M.
    Siobhan Ng
    Ozguroglu, Mustafa
    Gerritsen, Winald R.
    Mueller, Stefan
    Marttila, Timo
    Aparicio, Luis M. Anton
    Albers, Peter
    Gschwend, Juergen E.
    Bensfia, Samira
    Ecstein-Fraisse, Evelyne B.
    Bracarda, Sergio
    Heidenreich, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.
    Bavbek, Sevil E.
    Malik, Zafar
    Di Lorenzo, Giuseppe
    Scholz, Hans-Jorg
    van Oort, Inge M.
    Ng, Siobhan
    Ozguroglu, Mustafa
    Gerritsen, Winald R.
    Mueller, Stefan
    Marttila, Timo
    Anton-Aparicio, Luis M.
    Albers, Peter
    Gschwend, Juergen
    Bensfia, Samira
    Ecstein-Fraisse, Evelyne B.
    Bracarda, Sergio
    Heidenreich, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
12345